AZD9668 is a potent, selective and reversible inhibitor of human neutrophil elastase. It was developed as having the potential to be effective for neutrophil-driven inflammatory lung diseases, such as bronchiectasis and COPD [2
]. Since the phase II studies did not show clear efficacy for COPD this compound is now listed in the AstraZeneca Open Innovation Clinical Compound Bank
for repurposing proposals.
There is ambiguity on PubChem in the assigned nomenclature and stuctures for this compound, as CID 71587812
has been incorrectly assigned alvelestat as a synonym.